HCPCS code A4641: Billing guide for radiopharmaceuticals

Key takeaways

HCPCS code A4641 covers radiopharmaceutical diagnostic agents not otherwise classified, used when no more specific HCPCS code exists for the agent being administered.

A4641 excludes PET radiopharmaceuticals, which use A9597 or A9598 instead. Fluciclovine F18 (Axumin) and iobenguane I-131 (Azedra) illustrate the switch-over rule, since both moved off NOC codes once CMS assigned them A9588 and A9590.

Claims for A4641 require documentation of the specific agent name, dosage, route of administration, and clinical indication. Missing any of these is the leading cause of denials.

Pabau’s claims management software validates required fields before a claim is sent, holds incomplete claims back, and gives a status dashboard for tracking submissions.

A denied A4641 claim almost always comes down to the same mistake. Someone bills the NOC code when a specific HCPCS code already exists, or leaves the agent name and dosage off the claim.

HCPCS code A4641 only applies when no dedicated code exists for the radiopharmaceutical, and only when the claim carries every detail Medicare requires. The rest comes down to two things: confirming the code has no dedicated replacement, and documenting the claim the way CMS expects.

HCPCS code A4641: What it covers, and where it doesn’t

HCPCS code A4641 describes a radiopharmaceutical diagnostic agent not otherwise classified, or NOC. It sits in the HCPCS Level II code set that CMS maintains as part of the A-range supply and drug codes. Use it only when the diagnostic radiopharmaceutical has no dedicated code of its own, and only for non-PET agents.

CMS does not allow A4641 on PET claims. PET agents without a dedicated code use A9597 or A9598 instead.

NOC codes like A4641 act as a placeholder for agents that already have FDA approval but no permanent, agent-specific HCPCS code yet. Once CMS assigns that permanent code, switch to it right away. Billing A4641 after a specific code exists is a common audit trigger.

A4641 code details at a glance

The table below summarizes the key attributes of HCPCS code A4641 for quick reference during claim preparation.

Which drugs get billed under HCPCS code A4641

A4641 applies only to non-PET diagnostic radiopharmaceuticals that lack a dedicated HCPCS code. PET tracers awaiting a permanent code use A9597 for tumor identification, or A9598 for non-tumor studies. Any agent, PET or non-PET, moves to its own code the moment CMS assigns one.

The key rule: A4641 never applies to PET radiopharmaceuticals, dedicated code or not. It covers only non-PET diagnostic agents that genuinely lack one. FDG (F-18 fluorodeoxyglucose) and other PET tracers use their own codes, or the PET-specific NOC codes A9597 and A9598, never A4641.

Check the AAPC HCPCS code lookup or the annual CMS HCPCS Level II file each year to confirm current code assignments.

The billing checklist coders miss before submitting A4641

Billing HCPCS code A4641 correctly comes down to place of service, claim fields, and payer-specific rules. These are the steps coders miss most often in radiology and nuclear medicine billing.

That discipline matters on the diagnosis side too. The same rigor that keeps a code like M15.2 clean applies when you pair a diagnosis with A4641.

• Confirm no specific HCPCS code exists for the agent before filing under A4641.
• Confirm the agent is not a PET tracer. Unclassified PET radiopharmaceuticals use A9597 (tumor identification) or A9598 (non-tumor identification). CMS does not allow A4641 on PET claims.
• Include the drug name on the claim (Box 19 on CMS-1500 or the equivalent electronic field for institutional claims). Without the drug name, the NOC code claim cannot be adjudicated.
• Report the dosage and unit of measure: quantity billed must reflect the actual units administered, not the full vial.
• Bill one unit per administration unless payer policy specifies otherwise.
• Pair with the correct companion procedure code. A4641 is typically submitted alongside the nuclear medicine procedure code for the study performed, for example CPT 78306 for whole-body bone imaging. Put the radiopharmaceutical code and the imaging procedure code on separate claim lines.
• Check payer-specific coverage policies before submission. Medicare, Medicaid, and commercial payers may have different coverage criteria and prior authorization requirements for the same agent.

Where A4641 gets billed, and where it often doesn’t

A4641 is billed almost exclusively in hospital outpatient settings. The table below covers the eligible place of service codes and their rate implications.

A4641 is most commonly billed in hospital outpatient settings. Office and independent diagnostic testing facility (IDTF) billing is possible for many non-PET nuclear medicine studies. Confirm eligibility against the payer’s local coverage determination (LCD) before billing from a non-hospital setting.

The modifiers that make or break an A4641 claim

Modifier selection for A4641 depends on the payer and the clinical circumstance. Applying the wrong modifier, or skipping a required one, is a fast path to a clean claim denial. That judgment call is still yours. What claims management software can do is check that the required fields are complete before the claim goes out.

JW has been mandatory for single-dose vial drugs under Medicare Part B since January 1, 2017. CMS created JZ as an optional modifier on January 1, 2023. It became mandatory on July 1, 2023, with claim rejections enforced from October 1, 2023.

Radiopharmaceuticals are typically supplied in single-dose vials, so one of these two modifiers should appear on virtually every A4641 claim line submitted to Medicare.

The documentation an A4641 claim needs to avoid denial

CMS and most commercial payers require specific clinical documentation to support A4641 claims. Missing details in the record drive most NOC radiopharmaceutical denials.

Digital documentation tools configured to capture each required element at check-in eliminate the most common missing-documentation failure. Also make sure your team follows HIPAA-compliant documentation practices when recording patient-specific drug and dosage information.

• Specific agent name: the exact drug name (e.g., “fluciclovine F18 injection” not just “PET tracer”) must appear in both the clinical record and on the claim.
• Dosage and unit of measure: millicuries (mCi) administered, not the full vial amount.
• Route of administration: the method used to administer the agent, typically intravenous injection for radiopharmaceutical agents billed under A4641.
• Clinical indication: the medical reason for the study, linked to a valid ICD-10 diagnosis code.
• Ordering physician information: name and NPI of the referring or ordering provider.
• Prior authorization number: required when the payer mandates prior authorization for the specific agent.
• Date of service and place of service: must match the imaging procedure code on the same claim.

When an A4641 claim needs prior authorization first

Prior authorization (PA) requirements for A4641 vary by payer. Traditional Medicare does not universally require PA for every radiopharmaceutical, but Medicare Advantage plans and state Medicaid programs often do.

This is especially true for a newly introduced agent still billed under the NOC code before the payer adds it to an approved formulary.

Checking PA requirements before scheduling the appointment avoids the costliest mistake. Administering the agent first, then losing reimbursement because authorization was never in place, is expensive and avoidable.

When submitting a PA request, payers typically want four things before they approve it:

• The patient’s diagnosis codes.
• The specific agent being requested.
• The clinical rationale, for example elevated PSA following definitive therapy for prostate cancer.
• The ordering physician’s credentials.

Check each payer’s LCD and coverage policy first. Prior auth criteria for the same agent can differ substantially between commercial plans.

How Medicare covers and pays for HCPCS code A4641

Medicare Part B covers A4641 in hospital outpatient settings under the Outpatient Prospective Payment System, or OPPS. Reimbursement is based on invoice cost plus a handling fee, rather than a fixed Ambulatory Payment Classification rate. This is because NOC radiopharmaceuticals have no established market rate when CMS first covers them.

This means the amount Medicare pays can vary with the acquisition cost the facility documents. The CMS fee schedule lookup and annual OPPS Addendum files confirm current payment rates. Also reference the procedure code fee schedule for context on how fee schedule structures work across different billing environments.

Which ICD-10 codes support an A4641 claim

The diagnosis codes submitted alongside A4641 must establish medical necessity for the study. Payers use the ICD-10 pairing to decide whether the imaging is covered under their policy. A4641 covers non-PET diagnostic radiopharmaceuticals broadly, not one drug, so the correct pairing always depends on the specific study and agent billed.

The same crosswalk logic shows up in codes like S24.3XXA: the diagnosis has to support the procedure, regardless of specialty. The table below lists representative ICD-10 codes used with non-PET A4641 studies.

Always verify the applicable ICD-10 codes against the payer’s current LCD for the specific study performed. Covered diagnosis codes are published in CMS LCDs and can vary between Medicare Administrative Contractors, or MACs.

The same crosswalk discipline that keeps a code like S31.607S clean keeps your A4641 documentation consistent across claim types.

The HCPCS codes coders confuse with A4641

A4641 sits within a small range of diagnostic radiopharmaceutical HCPCS codes, next to a separate NOC pair reserved for PET tracers. Knowing the adjacent codes prevents miscoding and helps coders transition when CMS assigns a new one.

The IVF CPT codes guide walks through the same specific-vs-NOC logic in a different billing category. The same crosswalk work that keeps a code like S25.509S clean carries over to A4641 too.

A few quick comparisons clear up the codes coders mix up most often.

A4641 vs. A4642: what’s the difference? Specificity. A4642 is reserved only for indium In-111 satumomab pendetide. Any other diagnostic radiopharmaceutical without a specific code uses A4641 instead.

A4641 vs. A9699: which one applies? Diagnostic vs. therapeutic. A4641 covers diagnostic imaging agents, while A9699 covers therapeutic agents delivered for treatment. Mixing the two up is an auditable error.

A4641 vs. A9597/A9598: how do you tell them apart? By imaging modality, not indication. A4641 never applies to a PET tracer, so any unclassified PET agent uses A9597 or A9598 instead, regardless of whether it targets a tumor.

Use the PGM HCPCS lookup tool to confirm current code assignments and check for newly added codes each year.

How Pabau reduces errors in A4641 billing

Nuclear medicine and radiology practices share a specific challenge with NOC radiopharmaceutical billing.

Documentation requirements are strict, prior authorization workflows depend on the payer, and a single missing field can sink an entire claim line. Practice management software built for clinical specialties addresses several of these failure points directly.

• Field validation before submission: Pabau checks that required claim fields, like the agent name, dosage, and diagnosis code, are complete before a claim goes out. That catches the missing detail that causes most NOC radiopharmaceutical denials.
• Documentation capture at point of care: Pabau’s documentation templates can be configured to require the agent name, dosage, route, and clinical indication before a claim is prepared. That builds compliance into the workflow instead of leaving it to a post-service review.
• Send-gating for incomplete claims: Pabau holds a claim back from submission until every required field is filled in. That way, an incomplete A4641 line never reaches the payer as a preventable denial.
• A status dashboard for every submission: Pabau’s dashboard shows where each claim sits in the submission process. That lets billing staff catch a stalled or rejected A4641 claim before it becomes a write-off.

Radiology and nuclear medicine are not the only practices that hit this problem. A regenerative medicine practice ordering an advanced diagnostic workup runs into the same documentation problem. So does a functional medicine practice building out a lab and imaging panel.

Reduce A4641 billing errors before they become denials

Pabau's claims management software validates required fields, holds incomplete claims back, and gives you a status dashboard, so A4641 claims reach the payer complete.

Book a demo

Conclusion

A4641 does one job. It covers a diagnostic radiopharmaceutical that genuinely has no dedicated code yet. Treat that status as temporary, and confirm it every time you bill the agent. CMS reassigns NOC drugs to permanent codes without much warning, and continuing to use A4641 afterward is what draws an audit.

A missing drug name, dosage, or waste modifier turns a routine claim into a denial someone has to chase down and resubmit. Build the habit of capturing that detail at check-in, before the claim is even drafted.

Pabau’s documentation templates capture the agent name, dosage, and clinical indication at the point of care. Its claims tools validate the required fields and hold a claim back until it’s complete. That way, a missing detail gets caught before it becomes a denial.

Book a demo to see how it fits your radiopharmaceutical billing workflow.

Continue your research

Curious how another supply-code NOC works in practice? HCPCS code A4652 walks through billing microcapillary tube sealant under a similarly narrow supply code.

Billing a home health visit instead of a hospital study? HCPCS code G0157 covers per-diem PTA billing in the home health setting.

Need the rules for a metabolic nutrition supply code? HCPCS code B4154 breaks down billing for special metabolic enteral formula.

Working with implanted cardiac devices instead of radiopharmaceuticals? HCPCS code C1824 explains billing for a cardiac contractility modulation generator.

Handling anesthesia billing on the same claim? CPT code 01670 covers anesthesia billing for shoulder and axilla procedures.

Frequently asked questions